Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. When we think about artificial intelligence ...
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. When we think about the current research in ...
Geographic atrophy (GA) is a condition that typically progresses slowly, with lesions expanding by about 1 square millimeter per year, leading to blind spots due to retinal deterioration. Treatment ...
A novel measure of geographic atrophy shows a stronger correlation with vision loss than the area of the lesion and could aid ...
Some foods have beneficial properties, whereas others can cause harm, especially where geographic atrophy (GA) is concerned. The dietary choices you make can accelerate the progression of this ...
Low vision rehabilitation (LVR) can help people with geographic atrophy (GA) make the most of their remaining vision and adapt to daily life. Programs are personalized and may include visual aids, ...
Designation earned for a one-time intravitreal gene therapy designed to inhibit two key complement cascade pathways Geographic atrophy is an advanced form of dry age-related macular degeneration, that ...
In GATHER2 open-label extension study, IZERVAY reduced GA growth 37-40.5% vs. projected sham, with earlier intervention resulting in greater protection of retinal tissue area Study results found no ...
Belite Bio, Inc. announced the completion of enrollment in its global PHOENIX trial, a pivotal Phase 3 study assessing the safety and effectiveness of its lead candidate, Tinlarebant, in reducing ...
Zipbio has signed an exclusive license agreement with Meiragtx Holdings plc to advance an AAV gene therapy for geographic atrophy. Under the agreement, Meiragtx will receive exclusive rights to Zipbio ...
Presentations include long-term GATHER2 open-label extension data, real-world treatment patterns on safety, and biomarker insights on geographic atrophy disease progression TOKYO, Oct. 8, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results